Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974782 | 0.92 | MAPT (0.58) | MAPTKMT2APOLBALDH1A1LMNA | |
| SCHEMBL24974601 | 0.90 | ROCK2 (0.54) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL21152067 | 0.89 | POLB (0.47) | MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL24974634 | 0.86 | POLB (0.56) | MAPTPOLBALDH1A1 | |
| SCHEMBL24974637 | 0.81 | KMT2A (0.48) | MAPTKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL24974541 | 0.80 | ALDH1A1 (0.52) | POLBALDH1A1 | |
| SCHEMBL24974592 | 0.80 | ALDH1A1 (0.46) | MAPTPOLBALDH1A1 | |
| SCHEMBL24974743 | 0.77 | OPRM1 (0.48) | — | |
| SCHEMBL21151780 | 0.74 | ROCK2 (0.45) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL24974573 | 0.74 | HDAC1 (0.42) | MAPTKMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | MAPT 4695/4885KMT2A 499/4885TP53 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.